• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov8
Kazia Therapeutics released FY2025 9 Months Earnings on November 7, 2025 (EST) with actual revenue of USD 582.56K and EPS of USD -10.4709
04:00
Kazia Therapeutics released FY2025 Q4 earnings on November 7, 2025 (EST) with actual revenue of USD 589.43K and EPS of USD -2.4923
04:00
Kazia Therapeutics released FY2025 Annual Earnings on November 7 (EST), actual revenue USD 1.186 M (forecast USD 38.5 K), actual EPS USD -12.2472 (forecast USD -0.0173)
04:00
Kazia Therapeutics released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 567.93K, actual EPS USD -2.4014
04:00
Nov3
Kazia Licenses PD-L1 Protein Degrader NDL2 from QIMR Berghofer
10:34
Oct28
CFA Analyst Recommends Buy for Kazia Therapeutics
10:22

Schedules & Filings

Schedules
Filings
Nov7
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 589.43 K, Net Income -3.343 M, EPS -2.4923

Jun10
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 6.933 K, Net Income -3.252 M, EPS -3.8242

Apr17
Reverse Stock Split(EST)

1-for-5 Reverse Stock Split

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
ASPC
24.010
+78.91%
+10.590
PCLA
0.4050
+74.49%
+0.173
DTCK
0.3951
+66.08%
+0.157
SOPA
1.820
+58.26%
+0.670
ECDA
1.150
+46.50%
+0.365
GAUZ
1.470
+44.12%
+0.450
CELG.RT
0.0698
+39.60%
+0.020
ASPCR
0.2500
+38.89%
+0.070
PAVS
2.170
+37.34%
+0.590
CUE
0.3248
+34.77%
+0.084
View More